Applications of organoid technology to brain tumors
CNS Neuroscience & Therapeutics · 2023-10 · 29 (10) · 2725-2743
DOI: 10.1111/cns.14272 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift CNS Neuroscience & Therapeutics, online erschienen am 29.05.2023. Verfasst von Jie Wen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China. Hauptthemen laut MEDLINE: Brain Neoplasms, Glioblastoma. Die Arbeit wurde bisher 43-mal zitiert (Crossref) und nennt 142 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.
Abstract (Originalsprache)
Lacking appropriate model impedes basic and preclinical researches of brain tumors. Organoids technology applying on brain tumors enables great recapitulation of the original tumors. Here, we compared brain tumor organoids (BTOs) with common models including cell lines, tumor spheroids, and patient‐derived xenografts. Different BTOs can be customized to research objectives and particular brain tumor features. We systematically introduce the establishments and strengths of four different BTOs. BTOs derived from patient somatic cells are suitable for mimicking brain tumors caused by germline mutations and abnormal neurodevelopment, such as the tuberous sclerosis complex. BTOs derived from human pluripotent stem cells with genetic manipulations endow for identifying and understanding the roles of oncogenes and processes of oncogenesis. Brain tumoroids are the most clinically applicable BTOs, which could be generated within clinically relevant timescale and applied for drug screening, immunotherapy testing, biobanking, and investigating brain tumor mechanisms, such as cancer stem cells and therapy resistance. Brain organoids co‐cultured with brain tumors (BO‐BTs) own the greatest recapitulation of brain tumors. Tumor invasion and interactions between tumor cells and brain components could be greatly explored in this model. BO‐BTs also offer a humanized platform for testing the therapeutic efficacy and side effects on neurons in preclinical trials. We also introduce the BTOs establishment fused with other advanced techniques, such as 3D bioprinting. So far, over 11 brain tumor types of BTOs have been established, especially for glioblastoma. We conclude BTOs could be a reliable model to understand brain tumors and develop targeted therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurosurgery, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Hypothalamic-pituitary Research Center, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, Hunan, China.
- Academy of Integrative Medicine, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
- Fujian Key Laboratory of Integrative Medicine in Geriatrics, Fujian University of Traditional Chinese Medicine, Fuzhou, Fujian, China.
ORCID-Profile: Jie Wen, Quan Cheng, Liyang Zhang, Zhixiong Liu
Förderung
- National Natural Science Foundation of China
- Natural Science Foundation of Hunan Province
Zitieren
APA
Wen, J., Liu, F., Cheng, Q., Weygant, N., Liang, X., Fan, F., Li, C., Zhang, L., & Liu, Z. (2023). Applications of organoid technology to brain tumors. CNS Neuroscience & Therapeutics, 29(10), 2725-2743. https://doi.org/10.1111/cns.14272
Vancouver
Wen J, Liu F, Cheng Q, Weygant N, Liang X, Fan F, et al. Applications of organoid technology to brain tumors. CNS Neuroscience & Therapeutics. 2023;29(10):2725-2743. doi:10.1111/cns.14272
BibTeX
@article{Wen2023,
author = {Wen, Jie and Liu, Fangkun and Cheng, Quan and Weygant, Nathaniel and Liang, Xisong and Fan, Fan and Li, Chuntao and Zhang, Liyang and Liu, Zhixiong},
title = {Applications of organoid technology to brain tumors},
journal = {CNS Neuroscience & Therapeutics},
year = {2023},
volume = {29},
number = {10},
pages = {2725--2743},
doi = {10.1111/cns.14272}
}
EUVIMED